BBMRI-LPC
BBMRI - Large Prospective Cohorts
| Coordinatore | HELSINGIN YLIOPISTO
Organization address
address: YLIOPISTONKATU 4 contact info |
| Nazionalità Coordinatore | Finland [FI] |
| Totale costo | 10˙484˙065 € |
| EC contributo | 8˙000˙000 € |
| Programma | FP7-INFRASTRUCTURES
Specific Programme "Capacities": Research infrastructures |
| Code Call | FP7-INFRASTRUCTURES-2012-1 |
| Funding Scheme | CP-CSA-Infra |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-02-01 - 2017-01-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
HELSINGIN YLIOPISTO
Organization address
address: YLIOPISTONKATU 4 contact info |
FI (HELSINGIN YLIOPISTO) | coordinator | 892˙411.97 |
| 2 |
CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER
Organization address
address: Cours Albert-Thomas 150 contact info |
FR (LYON CEDEX 08) | participant | 963˙659.23 |
| 3 |
UPPSALA UNIVERSITET
Organization address
address: SANKT OLOFSGATAN 10 B contact info |
SE (UPPSALA) | participant | 512˙575.94 |
| 4 |
FUNDACIO PRIVADA PARC CIENTIFIC DE BARCELONA
Organization address
address: Baldiri i Reixac, 10-12 contact info |
ES (BARCELONA) | participant | 494˙426.00 |
| 5 |
TARTU ULIKOOL
Organization address
address: ULIKOOLI 18 contact info |
EE (TARTU) | participant | 464˙626.31 |
| 6 |
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD contact info |
UK (LONDON) | participant | 460˙484.58 |
| 7 |
GENOME RESEARCH LIMITED
Organization address
address: THE GIBBS BUILDING, EUSTON ROAD 215 contact info |
UK (LONDON) | participant | 453˙734.00 |
| 8 |
KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN
Organization address
address: ISMANINGER STRASSE 22 contact info |
DE (MUENCHEN) | participant | 445˙605.17 |
| 9 |
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Organization address
address: Ingolstaedter Landstrasse 1 contact info |
DE (MUENCHEN) | participant | 349˙668.63 |
| 10 |
Medizinische Universitaet Graz
Organization address
address: AUENBRUGGERPLATZ 2 contact info |
AT (GRAZ) | participant | 299˙300.40 |
| 11 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | participant | 288˙681.60 |
| 12 |
CAMBRIDGE PROTEIN ARRAYS LTD
Organization address
address: "BABRAHAM HALL, BABRAHAM RESEARCH CAMPUS" contact info |
UK (CAMBRIDGE) | participant | 284˙466.00 |
| 13 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 245˙165.31 |
| 14 |
NORGES TEKNISK-NATURVITENSKAPELIGEUNIVERSITET NTNU
Organization address
address: HOGSKOLERINGEN 1 contact info |
NO (TRONDHEIM) | participant | 226˙315.17 |
| 15 |
TERVEYDEN JA HYVINVOINNIN LAITOS
Organization address
address: MANNERHEIMINTIE 166 contact info |
FI (HELSINKI) | participant | 223˙505.97 |
| 16 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 203˙263.31 |
| 17 |
ACADEMISCH ZIEKENHUIS GRONINGEN
Organization address
address: Hanzeplein 1 contact info |
NL (GRONINGEN) | participant | 166˙026.22 |
| 18 |
ISLENSK ERFDAGREINING EHF
Organization address
address: Sturlugata 8 contact info |
IS (REYKJAVIK) | participant | 165˙711.48 |
| 19 |
UNIVERSITY OF LEICESTER
Organization address
address: University Road contact info |
UK (LEICESTER) | participant | 163˙431.07 |
| 20 |
The Research Institute of the Mc Gill University Health Centre
Organization address
address: GUY STREET 2155 contact info |
CA (MONTREAL) | participant | 147˙840.00 |
| 21 |
STATENS SERUM INSTITUT
Organization address
address: ARTILLERIVEJ 5 contact info |
DK (KOBENHAVN S) | participant | 112˙589.17 |
| 22 |
LEGAL PATHWAYS BV
Organization address
address: KLAPHEKLAAN 8 contact info |
NL (AERDENHOUT) | participant | 62˙809.00 |
| 23 |
"MedLawconsult (Van Veen, Toegepast Gezondheidsrecht)"
Organization address
address: Javastraat 76 contact info |
NL (DEN HAAG) | participant | 56˙372.95 |
| 24 |
LATVIJAS BIOMEDICINAS PETIJUMU UN STUDIJU CENTRS
Organization address
address: RATSUPITES IELA 1 contact info |
LV (RIGA) | participant | 47˙561.50 |
| 25 |
PECSI TUDOMANYEGYETEM - UNIVERSITY OF PECS
Organization address
address: VASVARI PAL UTCA 4 contact info |
HU (PECS) | participant | 47˙561.50 |
| 26 |
SVEUCILISTE U SPLITU (UNIVERSITY OF SPLIT)
Organization address
address: LIVANJSKA 5 contact info |
HR (SPLIT) | participant | 47˙561.50 |
| 27 |
Wroclawskie Centrum Badan EIT+ Sp z o.o
Organization address
address: UL. STABLOWICKA 147 contact info |
PL (Wroclaw) | participant | 47˙561.50 |
| 28 |
NASJONALT FOLKEHELSEINSTITUTT
Organization address
address: Lovisenberggata 8 contact info |
NO (OSLO) | participant | 42˙944.76 |
| 29 |
UNIVERSITEIT MAASTRICHT
Organization address
address: Minderbroedersberg 4-6 contact info |
NL (MAASTRICHT) | participant | 42˙944.76 |
| 30 |
INTERNATIONAL PREVENTION RESEARCH INSTITUT-IPRI MANAGEMENT
Organization address
address: COURS LAFAYETTE 95 contact info |
FR (LYON) | participant | 41˙195.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'In recent years, biomedical research has crossed international borders in large, collaborative studies showing the value of multidisciplinarity and scale advantage. This has yielded valuable insights and some led to new and better medicines and treatments for diseases. However, disease-focused studies provide less insight in the real disease onset, the relative disease burden in the population, and the actual comparability of selected patients. Large prospective cohort (LPC) studies following up initially healthy participants for years or decades are considered more reliable and different diseases can be studied. LPC studies require large numbers of subjects which are costly but particularly benefited from the advent of high throughput techniques providing opportunities for powerful study designs. This project unites the large study sets of the European Biobanking and Biomolecular Research Infrastructure (BBMRI) and the International Agency for Research on Cancer (IARC), thus achieving a worldwide unique scale of integration. Specifically, we aim to:1)Evaluate/improve the harmonization of individual data on health, lifestyle and other exposures;2)Develop/implement harmonized definitions of diseases;3)Improve biobanking and research technologies and develop innovative solutions facilitating high-quality, fair access to samples and data;4)Provide free transnational access by users, through study proposals selected by an open, pan-European call;5)In the framework of these studies, generate and provide access to whole genome sequences, transcriptome, proteome, metabolome and methylome data;6)Build new public-private partnerships involving large-scale prospective cohorts, and strengthening existing ones, allowing transparent industrial access to academic expertise;7) Build a network transferring the expertise of established European large-scale biobanks to new biobank initiatives under development in other countries.'
Introduzione (Teaser)
A European project is uniting the study sets of the European Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) and other large trials such as the International Agency for Research on Cancer (IARC). The result will be a multidisciplinary, international research initiative on a uniquely massive scale that can deliver an unprecedented amount of data on diseases.
Descrizione progetto (Article)
Large prospective cohort (LPC) studies follow up initially healthy individuals and then for decades are considered more reliable for the study of disease data. However, they are costly as they require large numbers of subjects. The advent of high-throughput techniques confers particular advantages to LPC studies.
The http://www.bbmri-lpc-biobanks.eu (BBMRI-LPC) (BBMRI - Large prospective cohorts) project aims to facilitate scientists' access to LPC studies on human health and disease. The consortium has applied excellence in networking and training in its first phase to achieve its first scientific call in April 2014.
Dissemination has so far been very wide-reaching and includes the project website that now features a 'Helpdesk for the emerging biobanks' and a 'Biobanking article of the week'. Workshops, forum meetings and collection of a list of 54 emerging biobanks for training and networking have also been executed. The basis of a white paper has been prepared for promoting public-private partnerships within the legal arm of BBMRI, BBMRI-ERIC and BBMRI-LPC.
Participation in boards of bodies including Biological and Medical Sciences and Biomed Bridges has strengthened collaboration and networking efforts. Exploratory contacts with industry have also been initiated.
To obtain data on the available cohorts, members have drawn up approved standard operating procedures. Preparation of a report is underway on the ethical and legal requirements for access and large-scale transnational sharing of data and samples.
According to the Organisation for Economic Co-operation and Development (OECD), biobanks are an essential part of the infrastructure underpinning life sciences and biotechnology. The BBMRI-LPC research infrastructure will further implement European Research Area (ERA) visions by creating a network together with BBMRI to establish a centre of knowledge. This proposed network will promote development of innovative diagnostics and therapeutics in Europe, extending worldwide. The initiative will also facilitate multinational studies as a result of coordination and increased access to resources. Long term, the impacts should be felt in personalised medicine and other emerging new biomedical industries at the frontiers of health research.